Respiratory Medicine
Volume 101, Issue 5 , Pages 957-962 , May 2007

The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD: A pilot study

  • Mario Cazzola

      Affiliations

    • Department of Respiratory Medicine, Unit of Pneumology and Allergology, A. Cardarelli Hospital, Naples, Italy
    • Corresponding Author InformationCorresponding author.
    • Present address: Department of Internal Medicine, Unit of Respiratory Diseases, University of Rome Tor Vergata, Rome, Italy.
    • ,
  • Maria Gabriella Matera

      Affiliations

    • Department of Experimental Medicine, Unit of Pharmacology, 2nd University of Naples, Naples, Italy

Received 30 August 2006 ,Accepted 9 September 2006.

References 

  1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, 2005 [accessed August 26, 2006]. Available at: 〈http://www.goldcopd.com〉.
  2. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23:932–946
  3. Cazzola M, Di Marco F, Santus P, Boveri B, Verga M, Matera MG, et al. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm Pharmacol Ther. 2004;17:35–39
  4. Cazzola M, Centanni S, Santus P, Verga M, Mondoni M, di Marco F, et al. The functional impact of adding salmeterol and tiotropium in patients with stable COPD. Respir Med. 2004;98:1214–1221
  5. Cazzola M, Noschese P, Salzillo A, De Giglio C, D’Amato G, Matera MG. Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients. Respir Med. 2005;99:524–528
  6. van Noord JA, Aumann JL, Janssens E, Smeets JJ, Verhaert J, Disse B, et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J. 2005;26:214–222
  7. van Noord JA, Aumann JL, Janssens E, Verhaert J, Smeets JJ, Mueller A, et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest. 2006;129:509–517
  8. Tashkin D, Celli B, Decramer M, Burkhart D, Kesten S, Cassino C. Prescribing patterns according to COPD treatment guidelines in patients enrolled in a global clinical trial [abstract]. Proc Am Thorac Soc. 2006;3:A111
  9. Cazzola M, Matera MG, Donner CF. Long-acting β2 agonists and theophylline in stable chronic obstructive pulmonary disease. Thorax. 1999;54:730–736
  10. Cazzola M, Di Lorenzo G, Di Perna F, Calderaro F, Testi R, Centanni S. Additive effects of salmeterol and fluticasone or theophylline in COPD. Chest. 2000;118:1576–1581
  11. ZuWallack RL, Mahler DA, Reilly D, Church N, Emmett A, Rickard K, et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest. 2001;119:1661–1670
  12. Barnes PJ. Theophylline in chronic obstructive pulmonary disease: new horizons. Proc Am Thorac Soc. 2005;2:334–339
  13. Kirsten DK, Wegner RE, Jorres RA, Magnussen H. Effects of theophylline withdrawal in severe chronic obstructive pulmonary disease. Chest. 1993;104:1101–1107
  14. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br Med J. 2000;320:1297–1303
  15. Donohue JF. Combination therapy for chronic obstructive pulmonary disease: clinical aspects. Proc Am Thorac Soc. 2005;2:272–281
  16. Filuk RB, Easton PA, Anthonisen NR. Responses to large doses of salbutamol and theophylline in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis. 1985;132:871–874
  17. Thomas P, Pugsley JA, Stewart JH. Theophylline and salbutamol improve pulmonary function in patients with irreversible chronic obstructive pulmonary disease. Chest. 1992;101:160–165
  18. Nishimura K, Koyama H, Ikeda A, Izumi T. Is oral theophylline effective in combination with both inhaled anticholinergic agent inhaled β2-agonist in the treatment of stable COPD?. Chest. 1993;104:179–184
  19. Karpel JP, Kotch A, Zinny M, Pesin J, Alleyne W. A comparison of inhaled ipratropium, oral theophylline plus inhaled β-agonist, and the combination of all three in patients with COPD. Chest. 1994;105:1089–1094
  20. Nishimura K, Koyama H, Ikeda A, Sugiura N, Kawakatsu K, Izumi T. The additive effect of theophylline on a high-dose combination of inhaled salbutamol and ipratropium bromide in stable COPD. Chest. 1995;107:718–723
  21. Lefcoe NM, Toogood JH, Blennerhassett G, Baskerville J, Paterson NA. The addition of an aerosol anticholinergic to an oral beta agonist plus theophylline in asthma and bronchitis: a double-blind single dose study. Chest. 1982;82(3):300–305
  22. Yildiz F, Basyigit I, Yildirim E, Boyaci H, Ilgazli A. Different bronchodilator combinations have similar effects on health status in COPD. Pulm Pharmacol Ther. 2006;19:101–106
  23. Hanaoka Y, Teramoto S, Yamamoto H, Yamaguchi Y, Ouchi Y. Effects of the sustained release of theophylline, UnifilR, and tiotropium bromide on pulmonary function and exercise performance in patients with stable chronic obstructive pulmonary disease [abstract]. Proc Am Thorac Soc. 2006;3:A114
  24. Freiman JA, Chalmers TC, Smith H, Kuebler RR. The importance of β, the type II error, and sample size in the design and interpretation of the randomized controlled trial. In:  Bailar JC,  Mosteller F editor. Medical uses of statistics. Boston, USA: NEJM Books; 1992;p. 357–373
  25. Ram FS, Jardin JR, Atallah A, Castro AA, Mazzini R, Goldstein R, et al. Efficacy of theophylline in people with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. Respir Med. 2005;99:135–144
  26. Sullivan P, Bekir S, Jaffar Z, Page C, Jeffery P, Costello J. Anti-inflammatory effects of low-dose oral theophylline in atopic asthma. Lancet. 1994;343:1006–1008
  27. Boswell-Smith V, Cazzola M, Page CP. Are phosphodiesterase 4 inhibitors just more theophylline?. J Allergy Clin Immunol. 2006;117:1237–1243

PII: S0954-6111(06)00452-5

doi: 10.1016/j.rmed.2006.09.012

Respiratory Medicine
Volume 101, Issue 5 , Pages 957-962 , May 2007

Article Tools

* Image Usage & Resolution